Wanbury Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the mandatory certificate on April 06, 2026, covering the quarter ended March 31, 2026.

Regulatory Compliance Submission

The company submitted the certificate to both National Stock Exchange of India Limited and BSE Limited pursuant to Regulation 74(5) of SEBI regulations. This quarterly submission is a mandatory requirement for all listed companies to ensure proper dematerialisation procedures are followed.

Registrar Confirmation

The certificate was issued by M/s. Purva Sharegistry (India) Pvt. Ltd., the company's appointed Registrar and Share Transfer Agent. Purva Sharegistry holds SEBI Registration No. INR000001112 and is authorized to handle share transfer operations for the company.

Ms. Deepali Gaonkar, Compliance Officer at Purva Sharegistry, confirmed that all securities received from depository participants for dematerialisation during the quarter were properly processed. The registrar verified that security certificates were mutilated and cancelled after due verification, and depositories' names were substituted in the register of members within prescribed timelines.

Dematerialisation Activity

During the quarter from January 01, 2026 to March 31, 2026, the company processed dematerialisation requests for multiple shareholders. The activity included processing of share certificates across different folio numbers, with transactions ranging from 50 to 100 shares per certificate.

The submission confirms that Wanbury Limited maintains compliance with SEBI regulations regarding share dematerialisation procedures. The quarterly certificate demonstrates the company's commitment to regulatory adherence and proper maintenance of shareholder records through its registered transfer agent.

Wanbury has officially announced the strengthening of its well-known Coriminic brand through strategic pediatric-focused product launches, as disclosed under Regulation 30 of SEBI listing requirements. The pharmaceutical company has introduced two specialized formulations designed to address regulatory restrictions while maintaining effective treatment options for children's cold and respiratory symptoms.

Product Launch Details

The company's latest regulatory filing reveals the launch of two key products targeting the pediatric healthcare segment:

Regulatory Response Strategy

Wanbury's product development strategy directly responds to recent advisories and regulatory restrictions issued by the Drugs Controller General of India (DCGI). The regulatory body has limited the use of fixed-dose combinations containing Chlorpheniramine + Phenylephrine in children below 4 years due to safety concerns. The company has positioned these new formulations as a first-of-its-kind India-focused initiative to reposition Chlorpheniramine in a safer, indication-driven format for pediatric use.

Key Product Benefits

Coriminic CPM Drops offers several advantages for pediatric care:

Market Positioning

The strategic launch positions Wanbury to capture a significant share of the ₹861 crore Cold Preparation Liquid market while navigating the restrictions laid by DCGI. Coriminic NS Nasal Drops serves as a non-systemic nasal decongestant solution, providing localized relief for children from nasal congestion and helping physicians navigate treatment options within government regulatory boundaries.

Strategic Impact

With this expansion, Wanbury is poised to further consolidate its presence in the fast-growing children Cold Preparation Liquid market. The company's approach demonstrates its commitment to addressing healthcare needs in the regulated children's medicine segment while maintaining compliance with evolving regulatory requirements in the pediatric pharmaceutical space.